AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38062221 — intervention group
Group type: COMPARATOR
Intervention: Guidelines only (Control)
Number of subjects: 130
Study 38062421 — intervention group
Group type: EXPERIMENTAL
Intervention: SILS + 1
Number of subjects: 198
Study 38062421 — intervention group
Group type: COMPARATOR
Intervention: CLS
Number of subjects: 198
Study 38062475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 10 weeks focusing on anxiety
Number of subjects: 90
Study 38062475 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 90
Study 38062732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 0
Study 38062732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38062808 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy
Number of subjects: 27
Study 38063017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic stroke temporally associated with AF (ISTAF)
Number of subjects: 229565
Study 38063017 — intervention group
Group type: COMPARATOR
Intervention: Patients without ischemic stroke
Number of subjects: 229565
Study 38063017 — intervention group
Group type: COMPARATOR
Intervention: Patients with past ischemic stroke
Number of subjects: 229565
Study 38063184 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualised early rehabilitation and mobilisation intervention
Number of subjects: 169
Study 38063184 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric Early Rehabilitation and Mobilisation during InTensive care manual
Number of subjects: 169
Study 38063320 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 36
Study 38063320 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 36
Study 38063321 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic resistance strengthening
Number of subjects: 40
Study 38063321 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocol
Number of subjects: 40
Study 38063346 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran
Number of subjects: 2203
Study 38063346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2203
Study 38063930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic optic nerve sheath diameter (ONSD) measurement on days 1-3
Number of subjects: 100
Study 38063930 — intervention group
Group type: COMPARATOR
Intervention: EEG and SSEP (standard care)
Number of subjects: 100
Study 38064141 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive CMR-based evaluation of LA size and function including LA length and LA reservoir strain.
Number of subjects: 648
Study 38064141 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive CMR-based evaluation of LA size and function.
Number of subjects: 648
Study 38064153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg
Number of subjects: 70
Study 38064153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 38064219 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma Center Trauma-Sensitive Yoga (TCTSY) - 10 weekly, 60-minute group sessions
Number of subjects: 131
Study 38064219 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT) - 12 weekly, 90-minute group sessions
Number of subjects: 131
Study 38064241 — intervention group
Group type: EXPERIMENTAL
Intervention: 17q21 variants
Number of subjects: 0
Study 38064241 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38064260 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)-ketamine (0.3 mg/kg/h)
Number of subjects: 144
Study 38064260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 38064262 — intervention group
Group type: EXPERIMENTAL
Intervention: Average daily steps (measured using Fitbit-HR Charge 2)
Number of subjects: 20
Study 38064262 — intervention group
Group type: EXPERIMENTAL
Intervention: Average daily steps
Number of subjects: 20
Study 38064262 — intervention group
Group type: EXPERIMENTAL
Intervention: Step trajectories during treatment
Number of subjects: 20
Study 38064262 — intervention group
Group type: EXPERIMENTAL
Intervention: Step trajectories early in the trial
Number of subjects: 20
Study 38064262 — intervention group
Group type: EXPERIMENTAL
Intervention: Step trajectories across the full duration of the trial
Number of subjects: 20
Study 38064267 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure Messaging Only (SM-Only)
Number of subjects: 53
Study 38064267 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure Messaging with Coaching (SM+Coach)
Number of subjects: 53
Study 38064267 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 53
Study 38064268 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-to-stand video analysis-based app
Number of subjects: 686
Study 38064454 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal cardiac shock wave therapy (ECSW) combined with optimal drug therapy
Number of subjects: 102
Study 38064454 — intervention group
Group type: COMPARATOR
Intervention: Optimal drug therapy
Number of subjects: 102
Study 38064591 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment dual-phase contrast-enhanced cone-beam CT (CBCT) imaging
Number of subjects: 9
Study 38064591 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttreatment 90Y PET/CT scan
Number of subjects: 9
Study 38064972 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week virtual environment intervention
Number of subjects: 15
Study 38065202 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0
Study 38065203 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabatolimab plus hypomethylating agent (intravenous decitabine 20 mg/m2)
Number of subjects: 127
Study 38065203 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus hypomethylating agent (intravenous decitabine 20 mg/m2)
Number of subjects: 127
Study 38065203 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabatolimab plus hypomethylating agent
Number of subjects: 127
Study 38065203 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus hypomethylating agent
Number of subjects: 127
Study 38065200 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised open-lung approach (iOLA) ventilation strategy
Number of subjects: 1308
Study 38065200 — intervention group
Group type: COMPARATOR
Intervention: Standard lung-protective ventilation
Number of subjects: 1308
Study 38065280 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine Enhanced Asthma Management through the Emergency Department (TEAM-ED)
Number of subjects: 373
Study 38065280 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 373
Study 38065280 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAM-ED (only prepandemic data)
Number of subjects: 373
Study 38065280 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (only prepandemic data)
Number of subjects: 373
Study 38065326 — intervention group
Group type: EXPERIMENTAL
Intervention: LACbes device with no visible leak
Number of subjects: 141
Study 38065326 — intervention group
Group type: EXPERIMENTAL
Intervention: LACbes device with residual device patency (RDP)
Number of subjects: 141
Study 38065326 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of peri-device leak (PDL) at the lobe
Number of subjects: 141
Study 38065326 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy after 6 months in patients with PDL at the lobe
Number of subjects: 141
Study 38065326 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 141
Study 38065326 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum diameter of LAA orifice
Number of subjects: 141
Study 38065403 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored anti-smoking ads containing LGBTQ+ branding
Number of subjects: 2214
Study 38065403 — intervention group
Group type: COMPARATOR
Intervention: Control ads without LGBTQ+ branding
Number of subjects: 2214
Study 38065512 — intervention group
Group type: EXPERIMENTAL
Intervention: PillSense system (novel bleeding sensor)
Number of subjects: 126
Study 38065906 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD-495 75 mg
Number of subjects: 242
Study 38065906 — intervention group
Group type: COMPARATOR
Intervention: AAF 60 mg
Number of subjects: 242
Study 38066113 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotadutide
Number of subjects: 0
Study 38066113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38066113 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 0
Study 38066442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 10 cc sterile processed acellular hAF once daily for up to 5 days
Number of subjects: 47
Study 38066442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 38066454 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin (PRF)
Number of subjects: 36
Study 38066454 — intervention group
Group type: COMPARATOR
Intervention: Xenograft
Number of subjects: 36
Study 38066454 — intervention group
Group type: COMPARATOR
Intervention: Alloplastic bone grafting material
Number of subjects: 36
Study 38066459 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal isometric knee extension
Number of subjects: 22
Study 38066459 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal isometric hip abduction
Number of subjects: 22
Study 38066459 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength
Number of subjects: 22
Study 38066459 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall maximal isometric strength assessment
Number of subjects: 22
Study 38066471 — intervention group
Group type: COMPARATOR
Intervention: Rectal microbicide modalities (douche, insert, suppository)
Number of subjects: 0
Study 38066502 — intervention group
Group type: EXPERIMENTAL
Intervention: New Families home visiting program
Number of subjects: 228
Study 38066502 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional support
Number of subjects: 228
Study 38066502 — intervention group
Group type: EXPERIMENTAL
Intervention: Appraisal support
Number of subjects: 228
Study 38066502 — intervention group
Group type: EXPERIMENTAL
Intervention: QoL levels in pregnancy
Number of subjects: 228
Study 38066522 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-PD-1 immunotherapy
Number of subjects: 54
Study 38066564 — intervention group
Group type: EXPERIMENTAL
Intervention: AT101 (h1218-CART19)
Number of subjects: 12
Study 38066597 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (once weekly) plus standard treatment
Number of subjects: 38
Study 38066597 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment alone)
Number of subjects: 38
Study 38066597 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide group
Number of subjects: 38
Study 38066597 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 38066614 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote consultation (teleconsultation or video consultation)
Number of subjects: 1068
Study 38066614 — intervention group
Group type: COMPARATOR
Intervention: Conventional face-to-face consultation (control)
Number of subjects: 1068
Study 38066613 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclass 1 (patients with septic shock)
Number of subjects: 98
Study 38066613 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclass 2 (patients with septic shock)
Number of subjects: 98
Study 38066613 — intervention group
Group type: COMPARATOR
Intervention: Noninfected controls without shock
Number of subjects: 98
Study 38066644 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan (0.16 mg/kg/week)
Number of subjects: 128
Study 38066644 — intervention group
Group type: COMPARATOR
Intervention: Daily GH (0.034 mg/kg/day)
Number of subjects: 128
Study 38066658 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 70
Study 38066658 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 70
Study 38066658 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 70
Study 38066658 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 70
Study 38067150 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 protein levels of ≥6.4 pg/mL
Number of subjects: 1002
Study 38067150 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants (rs1800795, rs1800797)
Number of subjects: 1002
Study 38067353 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning models incorporating CT imaging features
Number of subjects: 255
Study 38068424 — intervention group
Group type: EXPERIMENTAL
Intervention: Vojta therapy
Number of subjects: 0
Study 38068424 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38068820 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Number of subjects: 12
Study 38068820 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 12
Study 38068830 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal photographs paired with traditional food records using the Bitesnap app.
Number of subjects: 110
Study 38068830 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Self-Administered 24-h Dietary Assessment Tool (ASA24) for food records.
Number of subjects: 110
Study 38069986 — intervention group
Group type: EXPERIMENTAL
Intervention: TricValve system
Number of subjects: 44
Study 38070031 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNβ-1a plus 2 gm of metformin once daily
Number of subjects: 80
Study 38070031 — intervention group
Group type: COMPARATOR
Intervention: IFNβ-1a alone
Number of subjects: 80
Study 38070039 — intervention group
Group type: EXPERIMENTAL
Intervention: Safinamide as add-on to levodopa
Number of subjects: 854
Study 38070039 — intervention group
Group type: COMPARATOR
Intervention: Placebo as add-on to levodopa
Number of subjects: 854
Study 38070132 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sleep duration (IN) for 1 week (1 hour 30 min/night increase)
Number of subjects: 43
Study 38070132 — intervention group
Group type: COMPARATOR
Intervention: Habitual sleep (HB) for 1 week
Number of subjects: 43
Study 38070132 — intervention group
Group type: COMPARATOR
Intervention: Decreased sleep (DE) for 1 week (1 hour 19 min/night decrease)
Number of subjects: 43
Study 38070147 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 44
Study 38070159 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab plus chemotherapy
Number of subjects: 317
Study 38070159 — intervention group
Group type: COMPARATOR
Intervention: placebo plus chemotherapy
Number of subjects: 317
Study 38070309 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided femoral nerve block performed by specially trained nurses (Group Nurse)
Number of subjects: 42
Study 38070309 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided femoral nerve block performed by anaesthesiologists (Group Anaesthesiologist)
Number of subjects: 42
Study 38070309 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Group
Number of subjects: 42
Study 38070309 — intervention group
Group type: COMPARATOR
Intervention: Anaesthesiologist Group
Number of subjects: 42
Study 38070309 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 38070597 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant atezolizumab
Number of subjects: 151
Study 38070597 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual determination of percent viable tumor
Number of subjects: 151
Study 38070597 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally assessed percent viable tumor
Number of subjects: 151
Study 38070597 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally assessed major PathR
Number of subjects: 151
Study 38070635 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors (alirocumab 150 mg sc or evolocumab 140 mg sc every two weeks)
Number of subjects: 100
Study 38070635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 38070683 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa extract (CE) 500 mg flavanols/d, including 80 mg (-)-epicatechin
Number of subjects: 573
Study 38070683 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa extract (CE)
Number of subjects: 573
Study 38070683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 573
Study 38070682 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid-containing supplements during treatment
Number of subjects: 290
Study 38070682 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid in plasma at diagnosis
Number of subjects: 290
Study 38070682 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid in plasma during treatment
Number of subjects: 290
Study 38070868 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadership and Organizational Change for Implementation strategy plus training and technical assistance in MBC
Number of subjects: 234
Study 38070868 — intervention group
Group type: COMPARATOR
Intervention: Training and technical assistance only
Number of subjects: 234
Study 38070883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabrol shunt
Number of subjects: 3283
Study 38070883 — intervention group
Group type: COMPARATOR
Intervention: Non-Cabrol shunt
Number of subjects: 3283
Study 38070883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabrol shunt (without root replacement)
Number of subjects: 3283
Study 38070883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabrol shunt (with root replacement)
Number of subjects: 3283
Study 38070892 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 cases
Number of subjects: 3860
Study 38070892 — intervention group
Group type: COMPARATOR
Intervention: Population controls
Number of subjects: 3860
Study 38070892 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination status
Number of subjects: 3860
Study 38070892 — intervention group
Group type: EXPERIMENTAL
Intervention: Household contacts
Number of subjects: 3860
Study 38070892 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody levels
Number of subjects: 3860
Study 38070892 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-COVID impact
Number of subjects: 3860
Study 38070890 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest and multivariable logistic regression for predicting incident AF
Number of subjects: 0
Study 38070890 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher predicted risk of AF
Number of subjects: 0
Study 38070890 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower predicted risk of AF
Number of subjects: 0
Study 38070895 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional ultrasound (muscle US) techniques
Number of subjects: 1000
Study 38070904 — intervention group
Group type: EXPERIMENTAL
Intervention: Current criteria for VAP surveillance in Brazil
Number of subjects: 0
Study 38070904 — intervention group
Group type: COMPARATOR
Intervention: CDC-defined VAE criteria
Number of subjects: 0
Study 38070906 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa (triptorelin)
Number of subjects: 500
Study 38070906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 38070914 — intervention group
Group type: EXPERIMENTAL
Intervention: Rockwood Clinical Frailty Scale (CFS)
Number of subjects: 2
Study 38070914 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail NonDisabled Questionnaire
Number of subjects: 2
Study 38070914 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare Improvement Scotland FRAIL tool
Number of subjects: 2
Study 38070914 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial Clinical Evaluation
Number of subjects: 2
Study 38070914 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-item modified Frailty Index
Number of subjects: 2
Study 38070914 — intervention group
Group type: COMPARATOR
Intervention: Surgical procedure
Number of subjects: 2
Study 38070914 — intervention group
Group type: COMPARATOR
Intervention: Prognostic value comparison
Number of subjects: 2
Study 38070914 — intervention group
Group type: COMPARATOR
Intervention: Continuous outcome variables analysis
Number of subjects: 2
Study 38070914 — intervention group
Group type: COMPARATOR
Intervention: Interuser agreement comparison
Number of subjects: 2
Study 38070920 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy using Neurohawk or Solitaire FR
Number of subjects: 207
Study 38070920 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy with ICA occlusion
Number of subjects: 207
Study 38070920 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy with initial NIHSS score ≥17
Number of subjects: 207
Study 38070920 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy with final mTICI score 2b
Number of subjects: 207
Study 38070920 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy with more than one pass
Number of subjects: 207
Study 38070921 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterus transplantation (UTx)
Number of subjects: 210
Study 38070928 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC)
Number of subjects: 56
Study 38070928 — intervention group
Group type: COMPARATOR
Intervention: Placebo cryotherapy
Number of subjects: 56
Study 38070928 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (WBC and placebo)
Number of subjects: 56
Study 38071300 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 19
Study 38071300 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 19
Study 38071379 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus zanubrutinib for 12 cycles
Number of subjects: 48
Study 38071422 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir 400 mg twice daily (b.i.d.)
Number of subjects: 0
Study 38071422 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir 400 mg b.i.d.
Number of subjects: 0
Study 38071422 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir (400, 800, or 1200 mg b.i.d.)
Number of subjects: 0
Study 38071422 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir
Number of subjects: 0
Study 38071462 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziritaxestat
Number of subjects: 0